Immutep's LAG-3 Drug Fails Phase 3 Lung Cancer Study

Why It Matters

The miss undermines confidence in LAG‑3 checkpoint blockade and could delay further development, impacting investors and the broader immuno‑oncology landscape.

Key Takeaways

• Phase 3 NSCLC trial failed primary overall survival endpoint
• Approximately 600 patients received eftilagimod‑alpha plus chemotherapy
• No significant difference in progression‑free survival observed
• Safety comparable to chemotherapy alone
• LAG‑3 monotherapy prospects now questioned

Pulse Analysis

The LAG‑3 pathway has been touted as the next frontier in immune checkpoint therapy, following the commercial success of relatlimab‑nivolumab combos. Immutep, a pioneer with its LAG‑3 agonist eftilagimod‑alpha, aimed to leverage this momentum by pairing the agent with standard chemotherapy in a large Phase 3 trial for advanced non‑small cell lung cancer (NSCLC). Analysts had projected a potential new standard‑of‑care if the drug could demonstrate a survival advantage, positioning Immutep as a key player in the checkpoint arena.

When the data were released, the study’s primary endpoint—overall survival—was not met, with hazard ratios hovering around unity and confidence intervals crossing the prespecified threshold. Secondary measures, including progression‑free survival and objective response rates, similarly failed to show meaningful improvement. While adverse events were on par with chemotherapy alone, the absence of efficacy signals effectively nullifies the trial’s commercial promise. The market reacted sharply, with Immutep’s share price tumbling and investors questioning the viability of LAG‑3 monotherapy strategies.

The broader implication extends beyond Immutep. The failure adds to a growing body of evidence that LAG‑3 inhibition may require synergistic partners, such as PD‑1/PD‑L1 blockers, to unlock therapeutic benefit. Companies now face pressure to redesign trial designs, explore combination regimens, or pivot to alternative indications. For the oncology community, the result underscores the complexity of immune modulation and reinforces the need for robust biomarker strategies to identify patients most likely to respond to next‑generation checkpoint inhibitors.